Semaglutide Moves 40.4% of Children Below Obesity Threshold in Novo Nordisk Trial
Key Facts
Novo Nordisk said 40.4% of children with obesity who received once-weekly semaglutide moved below the obesity threshold after 68 weeks, compared with 0% on placebo, in the Phase 3 STEP Young trial involving 165 children aged 6 to under 12.
The 40.4% figure requires a methodological qualification because it is based on an estimate assuming all children adhered to treatment. The study used American age- and sex-specific growth charts, which define pediatric obesity as a BMI at or above the 95th percentile.
The STEP Young trial met its primary endpoint by showing a greater BMI reduction with semaglutide than placebo, but the top-line announcement did not disclose the size of the reduction. The trial was randomized, double-blind, placebo-controlled and multinational.
Both groups received a reduced-calorie diet and increased physical activity. Children assigned to semaglutide received a maximum dose of either 1.7 mg or 2.4 mg, based on their weight at the start of the trial.
More than 85% of participants had class 2 or class 3 severe obesity at baseline. The company said safety and tolerability were consistent with earlier trials and that no new concerns involving growth or pubertal development were identified; however, these are sponsor-reported top-line results rather than a published, peer-reviewed study.
The potential commercial significance is that the current American Wegovy label establishes use of the injection for weight management in patients with obesity aged 12 and older, while safety and effectiveness for that purpose have not been established below age 12. STEP Young could therefore support a future expansion into a younger group, but the result is not a regulatory approval and does not guarantee a sales impact.
Detailed findings are scheduled for presentation at ObesityWeek 2026, The Obesity Society's annual meeting in Washington, from November 14 to 17, 2026. Full efficacy and safety data will be necessary to assess clinical significance and any subsequent regulatory path.